Fluxome Sciences raises investment to accelerate research  

2005.11.30
Danish biotech company Fluxome Sciences has gained a DKK 45 m investment from Spef Venture, a leading venture capital firm in France, and Denmark's Vecata and Incuba Venture

Fluxome Sciences, a Danish biotech company specialising in bio-based production of chemical compounds, has gained a DKK 45 m (USD 7.2 m) investment from Spef Venture, a leading venture capital firm in France, and Denmark's Vecata and Incuba Venture. The money will be spent to accelerate research and product development.

Isabelle de Cremoux, director of the life sciences department at Spef Venture comments: "We target product focused companies with robust, highly innovative technology on rapidly growing markets. Fluxome Sciences' expertise in metabolic engineering of yeast applied to the huge, fast growing market of health ingredients convinced us".

Fluxome Sciences was founded in 2002 as a spin-out from the Technical University of Denmark. The firm focuses on bio-based production of ingredients for food, pharmaceuticals and nutraceuticals. Fluxome Sciences builds improved cell factories, enhances production yields and optimises bioprocesses. The company is located in Lyngby, north of Copenhagen. The news was reported by national daily newspaper Jyllands-Posten.

Link > Fluxome Sciences 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×